# Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

> **NCT05698017** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cytora Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Multiple System Atrophy
- MSA - Multiple System Atrophy

## Interventions

- **BIOLOGICAL:** hOMSC300

## Key facts

- **NCT ID:** NCT05698017
- **Lead sponsor:** Cytora Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-07
- **Primary completion:** 2026-02-19
- **Final completion:** 2026-02-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05698017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05698017, "Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05698017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*